Cited 21 times in
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권혁문 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2015-01-06T17:28:16Z | - |
dc.date.available | 2015-01-06T17:28:16Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0002-8703 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100040 | - |
dc.description.abstract | BACKGROUND: There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation. METHODS: Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up. RESULTS: A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7% of patients. Stents ≥28 mm in length were implanted in 58.1% of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3% in DAPT vs 1.9% in TAPT, log-rank P = .799). CONCLUSIONS: In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN HEART JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Coronary Angiography | - |
dc.subject.MESH | Coronary Artery Disease/diagnostic imaging | - |
dc.subject.MESH | Coronary Artery Disease/therapy* | - |
dc.subject.MESH | Coronary Restenosis/prevention & control | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/administration & dosage | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/pharmacology | - |
dc.subject.MESH | Tetrazoles/administration & dosage* | - |
dc.subject.MESH | Ticlopidine/administration & dosage | - |
dc.subject.MESH | Ticlopidine/analogs & derivatives* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Young Jin Youn | - |
dc.contributor.googleauthor | Jun-Won Lee | - |
dc.contributor.googleauthor | Sung Gyun Ahn | - |
dc.contributor.googleauthor | Seung-Hwan Lee | - |
dc.contributor.googleauthor | Hyunmin Choi | - |
dc.contributor.googleauthor | Cheol Woong Yu | - |
dc.contributor.googleauthor | Young Joon Hong | - |
dc.contributor.googleauthor | Hyuck Moon Kwon | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Junghan Yoon | - |
dc.identifier.doi | 10.1016/j.ahj.2013.08.028 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00260 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J00069 | - |
dc.identifier.eissn | 1097-6744 | - |
dc.identifier.pmid | 24439986 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S000287031300608X | - |
dc.contributor.alternativeName | Kwon, Hyuck Moon | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Kwon, Hyuck Moon | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 167 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 241 | - |
dc.citation.endPage | 248.e1 | - |
dc.identifier.bibliographicCitation | AMERICAN HEART JOURNAL, Vol.167(2) : 241-248.e1, 2014 | - |
dc.identifier.rimsid | 55456 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.